Corvus Pharmaceuticals
CRVS
62 hedge funds and large institutions have $159M invested in Corvus Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 18 increasing their positions, 9 reducing their positions, and 3 closing their positions.
1,029% more call options, than puts
Call options by funds: $6.07M | Put options by funds: $538K
500% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 3
216% more capital invested
Capital invested by funds: $50.2M → $159M (+$108M)
100% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 9
32% more funds holding
Funds holding: 47 → 62 (+15)
3.89% more ownership
Funds ownership: 44.11% → 48% (+3.9%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
+$5.38M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.77M |
| 3 |
GTC
Ghost Tree Capital
New York
|
+$1.8M |
| 4 |
Goldman Sachs
New York
|
+$1.35M |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
+$1.19M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Samlyn Capital
New York
|
-$5.72M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.44M |
| 3 |
TL
TowerView LLC
New York
|
-$1.01M |
| 4 |
Renaissance Technologies
New York
|
-$637K |
| 5 |
Two Sigma Advisers
New York
|
-$187K |
CRVS Hedge Fund Activity: Q3 2024 in Review
62 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Corvus Pharmaceuticals (CRVS) for Q3 2024, worth a combined $159M — up 216% from $50.2M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new CRVS positions and 3 closed out — a net gain of 15 holders — while 18 added to existing stakes and 9 trimmed.
The largest buyer was Vivo Capital, opening a new position worth an estimated $5.38M. The largest seller was Samlyn Capital, cutting an estimated $5.72M.
- 62 institutional investors held Corvus Pharmaceuticals (CRVS) as of Q3 2024, up from 47 in Q2 2024.
- Funds reported $159M of Corvus Pharmaceuticals stock for Q3 2024, up 216% quarter-over-quarter.
- 18 funds opened new Corvus Pharmaceuticals positions in Q3 2024 and 3 closed out, a net change of +15 holders.
- The largest Corvus Pharmaceuticals buyer in Q3 2024 was Vivo Capital, an estimated $5.38M added.
- The largest Corvus Pharmaceuticals seller in Q3 2024 was Samlyn Capital, an estimated $5.72M sold.
Based on aggregated 13F filings for Q3 2024.